When was Morphobloc founded?

Morphobloc was founded in 2016.

Where is Morphobloc located?

Morphobloc is headquartered in Umea, Sweden.

How many employees does Morphobloc have?

As of Jun 30, 2026, the latest employee count at Morphobloc is 1.

Where does Morphobloc rank among its competitors?

Morphobloc ranks 10th amongst 30 active competitors, of which 8 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was F2g, which secured $100M in Sep, 2024.

Who are the top competitors of Morphobloc?

Morphobloc's top competitors include Scynexis, F2g and Pulmocide. Among them, F2g secured the most recent funding round in September, 2024.

Morphobloc - 2026 Company Profile & Competitors

Company Details

Developer of antifungal agents to treat fungal diseases. The company has developed a novel class of antifungals to treat systemic, invasive and relapsing fungal diseases. It prevents the hyphal switching which serves as an essential virulence factor for fungal pathogens.

Key Metrics

Founded Year

2016

Location

Umea, Sweden

Stage

Unfunded

Ranked

10^th among 30 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

Scynexis & 37 more

View Morphobloc's full profile

Morphobloc has not raised any funding rounds yet.

Morphobloc's employee count trend

Morphobloc has 1 employees as of Jun 26. Here is Morphobloc's employee count trend over the years:

Uncover Morphobloc's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Morphobloc include Scynexis, F2g and Pulmocide. Here is the list of Top 10 competitors of Morphobloc, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scynexis 1999, Jersey City (United States), Public	Developing glucan synthase inhibitors for the treatment of fungal infections.	$62.7M	KBL, Societe Generale & 14 others	70/100
2nd	F2g 1998, Manchester (United Kingdom), Series H	Developer of therapeutic treatments for rare and life threatening infections	$353M	Morningside, Advent Life Sciences & 21 others	61/100
3rd	Pulmocide 2013, London (United Kingdom), Series C	Developer of inhaled antifungal medicines for treating respiratory lung infections	$205M	Pictet Group, Vivo Capital & 15 others	55/100
4th	Biosergen 2004, Solna (Sweden), Funding Raised	Developer of anti-fungal therapeutics for fungal infections	-	Rosetta Capital, BtoV	44/100
5th	Amplyx Pharmaceuticals 2006, San Diego (United States), Acqui-Hired	Pharmaceutical company focused on innovative medicines, vaccines, and expanded access programs	$144M	RiverVest Venture Partners, Sofinnova Investments ... & 17 others	41/100
6th	Elion Therapeutics 2024, New York City (United States), Series B	Developer of therapeutics for invasive fungal infections	$81M	Deerfield, AMR Action Fund & 1 others	39/100
7th	Viamet Pharmaceuticals 2005, Durham (United States), Acqui-Hired	Innovation hub revolutionizing healthcare, education, safety, energy, and technology with AI	$161M	Defense.gov, Woodford Investment Management ... & 7 others	35/100
8th	Mycovia Pharmaceuticals 2018, Durham (United States), Funding Raised	Developer of small molecule based therapeutics for the treatment of recurrent vulvovaginal candidiasis	-	NovaQuest Capital Management, HHS	32/100
9th	Hallux 2012, Laguna Hills (United States), Series B	Provider of subungual drug delivery technology for onychomycosis	$27.2M	Deerfield, OrthoArizona	32/100
10th	Morphobloc 2016, Umea (Sweden), Unfunded	Developer of antifungal agents to treat fungal diseases	-	-	30/100